IGFL4 Inhibitors
IGFL4 Inhibitors encompass a range of compounds that target different signaling pathways, which IGFL4 may be involved in either directly or indirectly. Compounds like LY294002 and Wortmannin are potent inhibitors of the PI3K/AKT pathway, a critical signaling cascade in cell survival and proliferation. Inhibition of PI3K leads to a reduction in AKT phosphorylation and subsequent downstream signaling, which could result in decreased IGFL4 activity, assuming that IGFL4 either participates in or is regulated by this pathway. Rapamycin further contributes to this inhibitory effect by targeting mTORC1, a downstream component of the PI3K/AKT pathway, which is also a central regulator of cell growth.
On the other hand, PP2 and Dasatinib inhibit Src family kinases, which are associated with a variety of cellular processes including proliferation, differentiation, and survival. The inhibition of these kinases results in decreased signaling through pathways that IGFL4 may utilize, thus potentially diminishing IGFL4 activity. PD98059 and U0126, both of which are MEK inhibitors, lead to reduced ERK activation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that blocks the PI3K/AKT pathway, which is crucial for cell survival and proliferation signals. Since IGFL4 is potentially involved in this pathway, LY294002 would inhibit the pathway's downstream signaling effects, thereby reducing the functional activity of IGFL4. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor that prevents the activation of AKT, a key mediator in multiple survival pathways. By inhibiting PI3K, Wortmannin ensures that AKT cannot be phosphorylated, leading to a decrease in IGFL4 activity if IGFL4 is indeed acting through this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that suppresses the mTORC1 complex downstream of PI3K/AKT signaling. Inhibition of mTORC1 by Rapamycin could decrease IGFL4's functional activity if it is involved in this pathway, by reducing cell growth and proliferation signals. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
A Src family kinase inhibitor that prevents activation of downstream signaling pathways involved in cell migration and proliferation. By inhibiting Src kinases, PP2 would reduce IGFL4 function if IGFL4 utilizes these kinases for signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor that blocks the MAPK/ERK pathway. Inhibition of this pathway by PD98059 would lead to decreased activation of ERK, which in turn could inhibit IGFL4 if IGFL4's activity is mediated through the MAPK/ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
An inhibitor of JNK, part of the MAPK signaling pathways. By inhibiting JNK, SP600125 could reduce the functional activity of IGFL4 if it relies on JNK for its signaling effects, particularly in stress response and apoptosis. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that reduces inflammation and other cellular responses by blocking p38 MAPK. If IGFL4's activity involves p38 MAPK signaling, then SB203580 would lead to decreased IGFL4 function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
An inhibitor of multiple tyrosine kinases, including Src family kinases. By inhibiting these kinases, Dasatinib can decrease signaling through pathways that could be utilized by IGFL4 for its cellular effects. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective inhibitor of MEK1/2, preventing the activation of the downstream kinase ERK. This inhibition could lower the activity of IGFL4 if it is involved in the MEK/ERK signaling pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A RAF kinase inhibitor that also targets several receptor tyrosine kinases. By inhibiting RAF kinase and subsequent MAPK/ERK signaling, Sorafenib could indirectly reduce IGFL4 activity. | ||||||